Skip to main content

Advertisement

Fig. 5 | EJNMMI Research

Fig. 5

From: Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy

Fig. 5

Time-dependent binding of 68Ga-PSMA-HBED-CC in (a) castration-resistant prostate cancer (CRPC) cells with and without coincubation with abiraterone acetate (AA, 5 μmol/L) and testosterone (T, 1 nmol/L) and (b) in androgen-sensitive revCRPC cells with and without AA-treatment (5 μmol/L) or additional withdrawal of testosterone (−T) from the medium. Displayed is the percentage uptake of applied radioactivity per 106 cells (mean ± SD; n = 9 cultures)

Back to article page